A Phase 1 interventional study of HYQVIA and HYQVIA in Healthy Volunteers, sponsored by Baxalta now part of Shire. Completed at 1 site in United States. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-14.
Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to assess the tolerability, safety, and pharmacokinetics of HYQVIA with ramp-up and no ramp-up dosing in healthy adult participants.
This study will comprise of Part 1 and Part 2. Each study part will consist of three treatment arms (Part 1 [approximately 24 participants]: Treatment Arms 1-3 and Part 2 [approximately 24 participants]: Treatment Arms 4-6). Treatment arms will be initiated in parallel within each study part. Each participant will participate in only one treatment arm. After participants in Treatment Arms 1-3 (Study Part 1) will complete Week 9, the tolerability and, safety data through Week 9 will be reviewed by a safety review team. (Participants in arms 1-3 will continue in the study as the safety review is being completed.) Once the safety review for Arms 1-3 (Study part 1) will be completed and approved, Treatment Arms 4-6 (Study Part 2) will begin.
Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
First submitted after Baxalta became part of Takeda.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Within 30 days prior to the first dose of investigational product:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a subcutaneous (SC) infusion of HYQVIA 0.1 g/kg (1/4 of TDL) on Day 1 and 8, 0.2 g/kg (1/2 of TDL) on Day 15, 0.3 g/kg (3/4 of TDL) on Day 29 followed by 0.4 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
Drug: HYQVIA
Participants received a SC infusion of HYQVIA 0.25 g/kg (1/4 of TDL) on Day 1 and 8, 0.5 g/kg (1/2 of TDL) on Day 15, 0.75 g/kg (3/4 of TDL) on Day 29 followed by 1.0 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
Drug: HYQVIA
Participants received a SC infusion of HYQVIA 0.2 g/kg (1/2 of TDL) on Day 1 and 15, followed by 0.4 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
Drug: HYQVIA
Participants received a SC infusion of HYQVIA 0.5 g/kg (1/2 of TDL) on Day 1 and 15, followed by 1.0 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
Drug: HYQVIA
Participants received a SC infusion of HYQVIA 0.4 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
Drug: HYQVIA
Participants received a SC infusion of HYQVIA 1.0 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
Drug: HYQVIA
Drug pages: Immunoglobulin G · Hyaluronoglucosaminidase
Participants received a SC infusion of HYQVIA 0.1 g/kg (1/4 of TDL) on Day 1 and 8, 0.2 g/kg (1/2 of TDL) on Day 15, 0.3 g/kg (3/4 of TDL) on Day 29 followed by 0.4 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
Also known as: IGI 10% with rHuPH20, Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
Drug pages: Immunoglobulin G · Hyaluronoglucosaminidase
Participants received a SC infusion of HYQVIA 0.25 g/kg (1/4 of TDL) on Day 1 and 8, 0.5 g/kg (1/2 of TDL) on Day 15, 0.75 g/kg (3/4 of TDL) on Day 29 followed by 1.0 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
Also known as: IGI 10% with rHuPH20, Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
Drug pages: Immunoglobulin G · Hyaluronoglucosaminidase
Participants received a SC infusion of HYQVIA 0.2 g/kg (1/2 of TDL) on Day 1 and 15, followed by 0.4 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
Also known as: IGI 10% with rHuPH20, Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
Drug pages: Immunoglobulin G · Hyaluronoglucosaminidase
Participants received a SC infusion of HYQVIA 0.5 g/kg (1/2 of TDL) on Day 1 and 15, followed by 1.0 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
Also known as: IGI 10% with rHuPH20, Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
Drug pages: Immunoglobulin G · Hyaluronoglucosaminidase
Participants received a SC infusion of HYQVIA 0.4 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
Also known as: IGI 10% with rHuPH20, Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
Drug pages: Immunoglobulin G · Hyaluronoglucosaminidase
Participants received a SC infusion of HYQVIA 1.0 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
Also known as: IGI 10% with rHuPH20, Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
Number of Participants Who Tolerated All Initiated HYQVIA Infusion
A tolerability event was considered to have occurred if an infusion was tolerable. An infusion was considered tolerable if the infusion rate was not reduced, or the infusion was not interrupted or stopped, due to an adverse event (AE) related to HYQVIA infusion. Tolerability was measured in terms of the number of participants for which the infusions was tolerable. Number of participants who tolerated all initiated HYQVIA Infusion were reported.
Time frame: From start of the study drug administration up to Week 9
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Treatment-emergent adverse events (TEAE) were defined as any event not present prior to the initiation of the treatments or any event already present that worsened in either intensity or frequency following exposure to the treatments. Number of participants with TEAEs was reported.
Time frame: From start of the study drug administration up to Week 25
Number of Participants Who Developed Binding and Neutralizing Antibodies to Recombinant Human Hyaluronidase PH20 (rHuPH20)
Binding antibodies are responsible for binding to a pathogen and alerting the immune system to its presence so white blood cells can be sent to destroy it. The antibody level (titer) in the blood tells health care provider whether or not participant been exposed to an antigen, or something that the body thinks is foreign. A neutralizing antibody (NAb) is an antibody that is responsible for defending cells from pathogens, which are organisms that cause disease. The number of participants who developed binding and neutralizing antibodies to rHuPH20 were reported.
Time frame: From start of the study drug administration up to Week 25
Time of Maximum Observed Serum Concentration (Tmax) of Total IgG and IgG Subclasses (IgG1, IgG2, IgG3, IgG4)
Tmax was a measure of the time to reach the maximum concentration in the plasma after the drug dose. Summarized baseline corrected data was reported.
Time frame: Pre-dose (Day 1), and 48, 96, 144 and 192 hours post-dose for all treatment arms; 360 hours post-dose for treatment arms 2 and 5; 360 and 696 hours post-dose for treatment arms 3 and 6
Maximum Observed Serum Concentration (Cmax) Sampled During a Dosing Interval of Total IgG and IgG Subclasses (IgG1, IgG2, IgG3, IgG4)
Cmax was a measure of the maximum amount of drug in the serum after the dose is given. Summarized baseline corrected data was reported.
Time frame: Pre-dose (Day 1), and 48, 96, 144 and 192 hours post-dose for all treatment arms; 360 hours post-dose for treatment arms 2 and 5; 360 and 696 hours post-dose for treatment arms 3 and 6
Area Under the Curve From the Time of Dosing to the Last Time Point With Measurable Concentration (AUClast) of Total IgG and IgG Subclasses (IgG1, IgG2, IgG3, IgG4)
AUClast was a measure of the total amount of drug in the plasma from time zero to time of the last measurable concentration. Summarized baseline corrected data was reported.
Time frame: Pre-dose (Day 1), and 48, 96, 144 and 192 hours post-dose for all treatment arms; 360 hours post-dose for treatment arms 2 and 5; 360 and 696 hours post-dose for treatment arms 3 and 6
Terminal Half-Life (T1/2) of Total IgG and IgG Subclasses (IgG1, IgG2, IgG3, IgG4)
T1/2 was the time required for a given drug concentration in the plasma to decrease by 50%. Summarized baseline corrected data was reported.
Time frame: Pre-dose (Day 1), and 48, 96, 144 and 192 hours post-dose for all treatment arms; 360 hours post-dose for treatment arms 2 and 5; 360 and 696 hours post-dose for treatment arms 3 and 6
Apparent Total Clearance After Extravascular Administration (CL/F) of Total IgG and IgG Subclasses (IgG1, IgG2, IgG3, IgG4)
Apparent clearance was a calculation of the rate at which a drug is removed from plasma after oral administration via renal, hepatic and other clearance pathways, expressed as volume (milliliters) per unit of time (minutes). Summarized baseline corrected data was reported.
Time frame: Pre-dose (Day 1), and 48, 96, 144 and 192 hours post-dose for all treatment arms; 360 hours post-dose for treatment arms 2 and 5; 360 and 696 hours post-dose for treatment arms 3 and 6
Apparent Volume of Distribution Associated With the Terminal Slope Following Extravascular Administration (Vz/F) of Total IgG and IgG Subclasses (IgG1, IgG2, IgG3, IgG4)
Volume of distribution (Vz/F) was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose is influenced by the fraction absorbed. Summarized baseline corrected data was reported.
Time frame: Pre-dose (Day 1), and 48, 96, 144 and 192 hours post-dose for all treatment arms; 360 hours post-dose for treatment arms 2 and 5; 360 and 696 hours post-dose for treatment arms 3 and 6
A total of 51 participants were enrolled in the study, 33 participants into the Ramp-Up dosing group (treatment arms \[TA\] 1, 2, 4, and 5) and 18 participants into the No Ramp-Up dosing group (TA 3 and TA 6).
| Milestone | Part 1 Schedule A: TA 1 (Low TDL HYQVIA) | Part 2 Schedule A: TA 4 (High TDL HYQVIA) | Part 1 Schedule B: TA 2 (Low TDL HYQVIA) | Part 2 Schedule B: TA 5 (High TDL HYQVIA) | Part 1 Schedule C: TA 3 (Low TDL HYQVIA) | Part 2 Schedule C: TA 6 (High TDL HYQVIA) |
|---|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 9 | 8 | 10 |
| Completed | 6 | 8 | 8 | 7 | 6 | 3 |
| Not completed | 2 | 0 | 0 | 2 | 2 | 7 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 1 | 0 | 2 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 1 | 5 |
| Withdrew: Non-compliance with study procedures | 0 | 0 | 0 | 0 | 1 | 0 |
A tolerability event was considered to have occurred if an infusion was tolerable. An infusion was considered tolerable if the infusion rate was not reduced, or the infusion was not interrupted or stopped, due to an adverse event (AE) related to HYQVIA infusion. Tolerability was measured in terms of the number of participants for which the infusions was tolerable. Number of participants who tolerated all initiated HYQVIA Infusion were reported.
| Participants | Part 1 Schedule A: TA 1 (Low TDL HYQVIA) | Part 2 Schedule A: TA 4 (High TDL HYQVIA) | Part 1 Schedule B: TA 2 (Low TDL HYQVIA) | Part 2 Schedule B: TA 5 (High TDL HYQVIA) | Part 1 Schedule C: TA 3 (Low TDL HYQVIA) | Part 2 Schedule C: TA 6 (High TDL HYQVIA) |
|---|---|---|---|---|---|---|
| Number of Participants Who Tolerated All Initiated HYQVIA Infusion | 7 | 8 | 8 | 9 | 8 | 10 |
Treatment-emergent adverse events (TEAE) were defined as any event not present prior to the initiation of the treatments or any event already present that worsened in either intensity or frequency following exposure to the treatments. Number of participants with TEAEs was reported.
| Participants | Part 1 Schedule A: TA 1 (Low TDL HYQVIA) | Part 2 Schedule A: TA 4 (High TDL HYQVIA) | Part 1 Schedule B: TA 2 (Low TDL HYQVIA) | Part 2 Schedule B: TA 5 (High TDL HYQVIA) | Part 1 Schedule C: TA 3 (Low TDL HYQVIA) | Part 2 Schedule C: TA 6 (High TDL HYQVIA) |
|---|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 8 | 8 | 8 | 9 | 8 | 10 |
Binding antibodies are responsible for binding to a pathogen and alerting the immune system to its presence so white blood cells can be sent to destroy it. The antibody level (titer) in the blood tells health care provider whether or not participant been exposed to an antigen, or something that the body thinks is foreign. A neutralizing antibody (NAb) is an antibody that is responsible for defending cells from pathogens, which are organisms that cause disease. The number of participants who developed binding and neutralizing antibodies to rHuPH20 were reported.
| Participants | Part 1 Schedule A: TA 1 (Low TDL HYQVIA) | Part 2 Schedule A: TA 4 (High TDL HYQVIA) | Part 1 Schedule B: TA 2 (Low TDL HYQVIA) | Part 2 Schedule B: TA 5 (High TDL HYQVIA) | Part 1 Schedule C: TA 3 (Low TDL HYQVIA) | Part 2 Schedule C: TA 6 (High TDL HYQVIA) |
|---|---|---|---|---|---|---|
| Binding ADA (Anti-Drug Antibodies) | 2 | 3 | 2 | 1 | 1 | 2 |
| Neutralizing ADA | 0 | 0 | 0 | 0 | 0 | 0 |
Tmax was a measure of the time to reach the maximum concentration in the plasma after the drug dose. Summarized baseline corrected data was reported.
| days | Part 1 Schedule A: TA 1 (Low TDL HYQVIA) | Part 2 Schedule A: TA 4 (High TDL HYQVIA) | Part 1 Schedule B: TA 2 (Low TDL HYQVIA) | Part 2 Schedule B: TA 5 (High TDL HYQVIA) | Part 1 Schedule C: TA 3 (Low TDL HYQVIA) | Part 2 Schedule C: TA 6 (High TDL HYQVIA) |
|---|---|---|---|---|---|---|
| Total IgG | 5.0 (2.0 to 8.0) | 4.0 (2.0 to 8.0) | 8.0 (6.0 to 16.0) | 6.0 (4.0 to 16.1) | 4.0 (4.0 to 15.0) | 6.0 (4.0 to 8.0) |
| Baseline corrected IgG1 | 5.0 (4.0 to 6.0) | 5.0 (4.0 to 8.0) | 7.0 (4.0 to 15.0) | 7.0 (6.0 to 8.0) | 6.0 (6.0 to 8.0) | 6.0 (4.0 to 8.0) |
| Baseline corrected IgG2 | 6.0 (2.0 to 8.0) | 7.0 (2.0 to 8.0) | 8.0 (4.0 to 15.0) | 6.0 (4.0 to 8.0) | 7.0 (4.0 to 16.1) | 7.0 (4.0 to 15.0) |
| Baseline corrected IgG3 | 5.0 (4.0 to 6.0) | 8.0 (6.0 to 16.0) | 8.0 (4.0 to 15.0) | 4.0 (4.0 to 8.0) | 7.0 (2.0 to 16.1) | 5.0 (4.0 to 8.0) |
| Baseline corrected IgG4 | 4.0 (4.0 to 4.0) | 8.0 (2.0 to 8.0) | 8.0 (4.0 to 15.0) | 8.0 (4.0 to 8.0) | 7.0 (4.0 to 8.0) | 6.0 (4.0 to 8.0) |
Cmax was a measure of the maximum amount of drug in the serum after the dose is given. Summarized baseline corrected data was reported.
| grams per liter (g/L) | Part 1 Schedule A: TA 1 (Low TDL HYQVIA) | Part 2 Schedule A: TA 4 (High TDL HYQVIA) | Part 1 Schedule B: TA 2 (Low TDL HYQVIA) | Part 2 Schedule B: TA 5 (High TDL HYQVIA) | Part 1 Schedule C: TA 3 (Low TDL HYQVIA) | Part 2 Schedule C: TA 6 (High TDL HYQVIA) |
|---|---|---|---|---|---|---|
| Total IgG | 2.70 ± 116.8 | 3.17 ± 66.8 | 3.10 ± 37.1 | 5.71 ± 41.0 | 5.34 ± 51.9 | 12.75 ± 16.2 |
| Baseline corrected IgG1 | 0.38 ± 58.5 | 1.51 ± 43.6 | 2.08 ± 25.1 | 1.11 ± 57.5 | 2.96 ± 36.2 | 5.88 ± 16.7 |
| Baseline corrected IgG2 | 0.48 ± 52.8 | 0.96 ± 52.6 | 1.33 ± 19.6 | 1.18 ± 74.8 | 1.98 ± 48.8 | 3.99 ± 41.9 |
| Baseline corrected IgG3 | 0.07 ± 5.7 | 0.03 ± 101.9 | 0.07 ± 26.4 | 0.04 ± 38.7 | 0.10 ± 67.6 | 0.19 ± 20.5 |
| Baseline corrected IgG4 | 0.02 | 0.08 ± 19.0 | 0.12 ± 46.8 | 0.13 ± 182.8 | 0.18 ± 32.7 | 0.29 ± 25.5 |
AUClast was a measure of the total amount of drug in the plasma from time zero to time of the last measurable concentration. Summarized baseline corrected data was reported.
| day*gram per liter (day*g/L) | Part 1 Schedule A: TA 1 (Low TDL HYQVIA) | Part 2 Schedule A: TA 4 (High TDL HYQVIA) | Part 1 Schedule B: TA 2 (Low TDL HYQVIA) | Part 2 Schedule B: TA 5 (High TDL HYQVIA) | Part 1 Schedule C: TA 3 (Low TDL HYQVIA) | Part 2 Schedule C: TA 6 (High TDL HYQVIA) |
|---|---|---|---|---|---|---|
| Total IgG | 9.63 ± 411.1 | 9.49 ± 39.0 | 31.60 ± 16.1 | 42.48 ± 43.3 | 70.39 ± 87.9 | 117.69 ± 65.5 |
| Baseline corrected IgG1 | 1.29 ± 46.6 | 11.37 ± 94.9 | 20.71 ± 60.1 | 4.30 ± 59.5 | 25.36 ± 51.6 | 60.04 ± 60.6 |
| Baseline corrected IgG2 | 1.66 ± 42.5 | 6.59 ± 102.1 | 17.36 ± 43.9 | 4.37 ± 49.7 | 17.77 ± 75.4 | 42.27 ± 86.3 |
| Baseline corrected IgG3 | 0.27 ± 27.4 | 0.22 ± 31.3 | 0.54 ± 79.0 | 0.17 ± 55.5 | 0.62 ± 90.5 | 1.33 ± 49.7 |
| Baseline corrected IgG4 | 0.06 | 0.40 ± 50.6 | 1.04 ± 45.8 | 0.39 ± 119.7 | 1.27 ± 75.3 | 2.43 ± 61.3 |
T1/2 was the time required for a given drug concentration in the plasma to decrease by 50%. Summarized baseline corrected data was reported.
| days | Part 1 Schedule A: TA 1 (Low TDL HYQVIA) | Part 2 Schedule A: TA 4 (High TDL HYQVIA) | Part 1 Schedule B: TA 2 (Low TDL HYQVIA) | Part 2 Schedule B: TA 5 (High TDL HYQVIA) | Part 1 Schedule C: TA 3 (Low TDL HYQVIA) | Part 2 Schedule C: TA 6 (High TDL HYQVIA) |
|---|---|---|---|---|---|---|
| Total IgG | — | — | — | — | 8.1 (5.9 to 10.3) | — |
Apparent clearance was a calculation of the rate at which a drug is removed from plasma after oral administration via renal, hepatic and other clearance pathways, expressed as volume (milliliters) per unit of time (minutes). Summarized baseline corrected data was reported.
| liters per day per kilograms (L/day/kg) | Part 1 Schedule A: TA 1 (Low TDL HYQVIA) | Part 2 Schedule A: TA 4 (High TDL HYQVIA) | Part 1 Schedule B: TA 2 (Low TDL HYQVIA) | Part 2 Schedule B: TA 5 (High TDL HYQVIA) | Part 1 Schedule C: TA 3 (Low TDL HYQVIA) | Part 2 Schedule C: TA 6 (High TDL HYQVIA) |
|---|---|---|---|---|---|---|
| Total IgG | — | — | — | — | 0.01 ± 19.3 | — |
Volume of distribution (Vz/F) was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose is influenced by the fraction absorbed. Summarized baseline corrected data was reported.
| Liter per kilogram (L/Kg) | Part 1 Schedule A: TA 1 (Low TDL HYQVIA) | Part 2 Schedule A: TA 4 (High TDL HYQVIA) | Part 1 Schedule B: TA 2 (Low TDL HYQVIA) | Part 2 Schedule B: TA 5 (High TDL HYQVIA) | Part 1 Schedule C: TA 3 (Low TDL HYQVIA) | Part 2 Schedule C: TA 6 (High TDL HYQVIA) |
|---|---|---|---|---|---|---|
| Total IgG | — | — | — | — | 0.07 ± 20.6 | — |
Collected over From start of the study drug administration up to Week 25. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 Schedule A: TA 1 (Low TDL HYQVIA) | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Part 2 Schedule A: TA 4 (High TDL HYQVIA) | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Part 1 Schedule B: TA 2 (Low TDL HYQVIA) | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Part 2 Schedule B: TA 5 (High TDL HYQVIA) | 0/9 (0%) | 0/9 (0%) | 9/9 (100%) |
| Part 1 Schedule C: TA 3 (Low TDL HYQVIA) | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Part 2 Schedule C: TA 6 (High TDL HYQVIA) | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Event | Part 1 Schedule A: TA 1 (Low TDL HYQVIA) | Part 2 Schedule A: TA 4 (High TDL HYQVIA) | Part 1 Schedule B: TA 2 (Low TDL HYQVIA) | Part 2 Schedule B: TA 5 (High TDL HYQVIA) | Part 1 Schedule C: TA 3 (Low TDL HYQVIA) | Part 2 Schedule C: TA 6 (High TDL HYQVIA) |
|---|---|---|---|---|---|---|
| Infusion site erythemaGeneral disorders | 5/8 | 6/8 | 5/8 | 9/9 | 6/8 | 10/10 |
| Infusion site painGeneral disorders | 3/8 | 5/8 | 6/8 | 9/9 | 5/8 | 7/10 |
| Infusion site swellingGeneral disorders | 8/8 | 8/8 | 8/8 | 9/9 | 8/8 | 10/10 |
| Infusion site pruritusGeneral disorders | 4/8 | 3/8 | 7/8 | 5/9 | 3/8 | 5/10 |
| PyrexiaGeneral disorders | 0/8 | 0/8 | 0/8 | 0/9 | 0/8 | 3/10 |
| HeadacheNervous system disorders | 1/8 | 0/8 | 1/8 | 0/9 | 2/8 | 2/10 |
| HypotensionVascular disorders | 0/8 | 0/8 | 0/8 | 0/9 | 0/8 | 2/10 |
| Blood pressure systolic decreasedInvestigations | 0/8 | 1/8 | 0/8 | 0/9 | 0/8 | 0/10 |
| ChillsGeneral disorders | 1/8 | 0/8 | 0/8 | 0/9 | 0/8 | 0/10 |
| DizzinessNervous system disorders | 0/8 | 0/8 | 1/8 | 0/9 | 0/8 | 1/10 |
The safety set included all enrolled participants who received at least 1 dose of HYQVIA.
| Age, Continuous(years) | Part 1 Schedule A: TA 1 (Low TDL HYQVIA) | Part 2 Schedule A: TA 4 (High TDL HYQVIA) | Part 1 Schedule B: TA 2 (Low TDL HYQVIA) | Part 2 Schedule B: TA 5 (High TDL HYQVIA) | Part 1 Schedule C: TA 3 (Low TDL HYQVIA) | Part 2 Schedule C: TA 6 (High TDL HYQVIA) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 28.9 ± 8.04 | 34.4 ± 6.44 | 40.4 ± 5.01 | 36.4 ± 7.88 | 36.8 ± 8.58 | 34.0 ± 10.07 | 35.1 ± 8.28 |
| Sex: Female, Male(Participants) | Part 1 Schedule A: TA 1 (Low TDL HYQVIA) | Part 2 Schedule A: TA 4 (High TDL HYQVIA) | Part 1 Schedule B: TA 2 (Low TDL HYQVIA) | Part 2 Schedule B: TA 5 (High TDL HYQVIA) | Part 1 Schedule C: TA 3 (Low TDL HYQVIA) | Part 2 Schedule C: TA 6 (High TDL HYQVIA) | Total |
|---|---|---|---|---|---|---|---|
| Female | 7 | 5 | 4 | 5 | 4 | 4 | 29 |
| Male | 1 | 3 | 4 | 4 | 4 | 6 | 22 |
| Ethnicity (NIH/OMB)(Participants) | Part 1 Schedule A: TA 1 (Low TDL HYQVIA) | Part 2 Schedule A: TA 4 (High TDL HYQVIA) | Part 1 Schedule B: TA 2 (Low TDL HYQVIA) | Part 2 Schedule B: TA 5 (High TDL HYQVIA) | Part 1 Schedule C: TA 3 (Low TDL HYQVIA) | Part 2 Schedule C: TA 6 (High TDL HYQVIA) | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 8 | 8 | 6 | 9 | 6 | 10 | 47 |
| Not Hispanic or Latino | 0 | 0 | 2 | 0 | 2 | 0 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1 Schedule A: TA 1 (Low TDL HYQVIA) | Part 2 Schedule A: TA 4 (High TDL HYQVIA) | Part 1 Schedule B: TA 2 (Low TDL HYQVIA) | Part 2 Schedule B: TA 5 (High TDL HYQVIA) | Part 1 Schedule C: TA 3 (Low TDL HYQVIA) | Part 2 Schedule C: TA 6 (High TDL HYQVIA) | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 4 | 3 | 2 | 2 | 17 |
| White | 4 | 6 | 4 | 6 | 6 | 8 | 34 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Oct 2020 to primary completion in Mar 2022, 16 months.
Results were first posted in Dec 2023, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Immunoglobulin G · Hyaluronoglucosaminidase